Faculty

Faculty

Alexander E Drilon

MD

Memorial Sloan-Kettering Cancer Center, New York, New York

Chief, Early Drug Development Service, Attending Physician, Thoracic Oncology Service

Weill Cornell Medical College, New York, New York

Professor

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-small cell lung cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of novel therapies for non-small cell lung cancer and the management of associated treatment-related toxicities in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Appreciate the incidence and clinical relevance of ROS1 gene alterations in metastatic non-small cell lung cancer (NSCLC), and recognize optimal approaches to identify these actionable abnormalities.
• Assess the pharmacologic similarities and differences among the various FDA-approved ROS1-targeted tyrosine kinase inhibitors (TKIs), and recognize the implications for the efficacy and tolerability of these agents.
• Understand published research findings and current guideline recommendations in order to counsel patients with ROS1-positive NSCLC regarding the selection and sequencing of therapy.
• Review available clinical trial data evaluating the efficacy and safety of ROS1 TKIs for patients with ROS1-positive NSCLC, and educate individuals regarding the benefits and risks of this therapeutic strategy.
• Recognize the spectrum, frequency, severity and optimal management of toxicities associated with ROS1-targeted TKIs to facilitate the safe and effective use of these agents.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

NUMBER OF CONTACT HOURS AWARDED
This educational activity for 1 contact hour is provided by RTP during the period of September 29, 2026 to September 29, 2027.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONU2026/TargetedLung/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION 
To receive credit for this activity, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Drilon is on advisory committees with Bayer HealthCare Pharmaceuticals, EcoR1 Capital LLC, Ellipses Pharma, Nuvalent, Nuvation Bio Inc and Zymeworks Inc; has consulting agreements with Bayer HealthCare Pharmaceuticals, Boundless Bio, Bristol Myers Squibb, Enlaza Therapeutics, Nuvalent, Nuvation Bio Inc, Regeneron Pharmaceuticals Inc, Treeline Biosciences and Two River; has contracted research with Foundation Medicine, GSK, Taiho Oncology Inc and Teva Oncology; holds a copyright for Selpercatinib-Osimertinib (US 18/041,617, pending); has received food/beverages from Boehringer Ingelheim Pharmaceuticals Inc, Merck and Puma Biotechnology Inc; holds stock options — private companies in Treeline Biosciences; and has nonrelevant financial relationships with UpToDate and Wolters Kluwer. All of these relevant financial relationships have been mitigated.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Nuvation Bio Inc.

Release date: September 29, 2026
Expiration date: September 29, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Bazhenova L et al. Taletrectinib in TKI-naïve patients with ROS1+ NSCLC: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT300.

Cho BC et al. Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Long-term follow-up from the phase 1/2 TRIDENT-1 trial. World Conference on Lung Cancer 2025;Abstract MA02.03.

Desilets A et al. Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. Cancer 2025;131(Suppl 1):e35784. Abstract

Drilon AE et al. Pivotal ARROS-1 efficacy and safety data: Zidesamtinib in TKI pre-treated patients with advanced/metastatic ROS1+ NSCLC. World Conference on Lung Cancer 2025;Abstract PL02.15.

Drilon AE et al. Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N Engl J Med 2024;390(2):118-31. Abstract

Krebs MG et al. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC. ESMO 2024;Abstract 1290P.

Liu G et al. Taletrectinib in TKI-pretreated patients with ROS1+ non-small cell lung cancer: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT244.

Pérol M et al. Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 2025;43(16):1920-9. Abstract

Peters S et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: The phase 2/3 BFAST trial. Nat Med 2024;30(7):1923-32. Abstract

Faculty

Nurse

Blanca Ledezma

MSN, NP, AOCNP

UCLA Health, Department of Hematology Oncology, Santa Monica, California

Nurse

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for breast cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant hormone receptor (HR)-positive metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with HR-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
• Review available research findings with serial ESR1 testing using circulating tumor DNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
• Appraise the scientific justification for, available data with and potential clinical role of oral SERDs as adjuvant treatment for patients with localized HR-positive, HER2-negative breast cancer.
• Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 30, 2026 to July 30, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Ledezma is on speakers bureaus for AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, and Pfizer Inc; and is on steering committees for AstraZeneca Pharmaceuticals LP. Ms Marti-Smith has consulting agreements with Amplity; is on speakers bureaus for AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, a Hologic Company, Daiichi Sankyo Inc, and Stemline Therapeutics Inc; and has nonrelevant financial relationships with ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, and Oncology Nursing News. Dr O’Regan is on advisory committees with Biotheranostics Inc, a Hologic Company; has consulting agreements with Biotheranostics Inc, a Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, and Regor Pharmaceuticals; has contracted research with Novartis and Puma Biotechnology Inc; and is on data and safety monitoring boards/committees for Gilead Sciences Inc.

MODERATOR — Dr McArthur is on advisory committees with Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, and Pfizer Inc; and has consulting agreements with ALX Oncology.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

Release date: July 30, 2026
Expiration date: July 30, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Faculty

Nurse

Caroline Kuhlman

MSN, APRN-BC

Massachusetts General Brigham Cancer Institute, Boston, Massachusetts

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers

Faculty

Philip A Philip

MD, PhD

Wayne State University Department of Oncology, Detroit, Michigan

Chair, Hematology and Oncology, Professor of Oncology and Pharmacology, Co-Leader, Pancreatic Cancer Program, Medical Director, Cancer Clinical and Translational Research Office, Chair, GI Cancer, SWOG, Henry Ford Cancer Institute

Nurse

Amanda K Wagner

APRN-CNP, AOCNP

The James Cancer Hospital, The Ohio State University, Columbus, Ohio

GI Malignancies

Moderator

Eileen M O’Reilly

MD

David M Rubenstein Center for Pancreatic Cancer Research, New York, New York

Winthrop Rockefeller Endowed Chair in Medical Oncology, Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers, Co-Director, Medical Initiatives

Memorial Sloan Kettering Cancer Center, New York, New York

Chair, Human Research Protection Program and IRB, Attending Physician, Member

Weill Cornell Medical College, New York, New York

Professor of Medicine

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with pancreatic cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for pancreatic cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and current clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available and emerging data with and ongoing research studies of novel agents designed to exploit this therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 22, 2026 to July 22, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/PancreaticCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip is on advisory committees with Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, and Revolution Medicines Inc; has consulting agreements with Novocure Inc; has contracted research with Bristol Myers Squibb, Novartis, Revolution Medicines Inc, and Taiho Oncology Inc; and is on data and safety monitoring boards/committees for J-Pharma Co Ltd and Oncolytics Biotech Inc.

MODERATOR — Dr O’Reilly is on advisory committees and has consulting agreements (uncompensated) with Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, and Tango Therapeutics; has contracted research with Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, and Tango Therapeutics; and has nonrelevant financial relationships with American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), and Stand Up 2 Cancer.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Ipsen Biopharmaceuticals Inc and Revolution Medicines Inc.

Release date: July 22, 2026
Expiration date: July 22, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Ahn DH et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: A retrospective analysis. Ther Adv Med Oncol 2017;9(2):75-82. Abstract

Anadkat MJ et al. Expert guidance on prophylaxis and treatment of dermatologic adverse events with tumor treating fields (TTFields) therapy in the thoracic region. Front Oncol 2023;12. Abstract

Babiker HM et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: Randomized, open-label, pivotal phase III PANOVA-3 Study. J Clin Oncol 2025;43(21):2350-60. Abstract

Ben-Aharon I et al. Early-onset cancer in the gastrointestinal tract is on the rise—Evidence and implications. Cancer Discov 2023;13(3):538-51. Abstract

Conroy T et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379(25):2395-406. Abstract

Gyawali B et al. WBC growth factors: ASCO guideline update. J Clin Oncol 2026;44(9):812-24. Abstract

Harrold E et al. Early-onset GI cancers: Rising trends, genetic risks, novel strategies, and special considerations. Am Soc Clin Oncol Educ Book 2023;43:e398068. Abstract

Hesketh PJ et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020;38(24):2782-97. Abstract

O’Reilly EM et al. Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC). AACR 2026;Abstract LB337.

Singhal A et al. Targeting KRAS in cancer. Nat Med 2024;30(4):969-83. Abstract

Stadler ZK et al. Therapeutic implications of germline testing in patients with advanced cancers. J Clin Oncol 2021;39(24):2698-709. Abstract

Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract

Wainberg ZA et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Gastrointestinal Cancers Symposium 2023;Abstract LBA661.

Wolpin BM et al. Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC). AACR 2026;Abstract LB407.

Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J Hematol Oncol 2024;17(1):108. Abstract

Faculty

Nurse

Michael Lai

MSN, ARNP, FNP-C

Fred Hutchinson Cancer Center, Seattle, Washington

Advanced Practice Provider

University of Washington School of Medicine, Seattle, Washington

Teaching Associate

Nurse

Stacy E Walker

FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Nurse Practitioner

Faculty

Evan Y Yu

MD

Fred Hutchinson Cancer Center, Seattle, Washington

Section Head, Medical Oncology, Clinical Research Division

Fred Hutchinson Cancer Research Consortium, Seattle, Washington

Medical Director, Clinical Research Support

University of Washington School of Medicine, Seattle, Washington

Professor of Medicine, Division of Hematology and Oncology, Department of Medicine

Moderator

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with prostate cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for prostate cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Appraise published research findings on optimal management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, and apply this information to educate patients about personalized treatment recommendations.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and identify patients for these strategies.
• Assess the available and emerging research supporting PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 21, 2026 to July 21, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/ProstateCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Mr Lai and Ms Walker have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Yu has consulting agreements with Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, and Tolmar; and has contracted research with Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, and Tyra Biosciences Inc.

MODERATOR — Dr Tagawa has consulting agreements with AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, and Telix Pharmaceuticals Limited; has contracted research with AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, and Telix Pharmaceuticals Limited; is on data and safety monitoring boards/committees for Boston Scientific Corporation; and has stock options — private companies in Convergent Therapeutics.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas, Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Release date: July 21, 2026
Expiration date: July 21, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Faculty

Faculty

Reva Basho

MD

Ellison Medical Institute, Los Angeles, California

Breast Medical Oncology, Chief Medical Officer

Nurse

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Nurse

Melissa Rikal

FNP-BC, AOCNP

Sarah Cannon Research Institute, Nashville, Tennessee

Nurse Practitioner

Moderator

Seth Wander

MD, PhD

Massachusetts General Hospital, Boston, Massachusetts

Director of Precision Medicine, Termeer Center for Targeted Therapies, Director of Translational Research, Breast Oncology Program

Harvard Medical School, Boston, Massachusetts

Assistant Professor of Medicine

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies targeting the PI3K/AKT/mTOR pathway in HR-positive metastatic breast cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
• Recognize the frequency of PIK3CA/AKT1/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and anticipated data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Recall the design of ongoing clinical trials evaluating novel agents targeting the PI3K/AKT/mTOR pathway, and counsel appropriate patients with HR-positive mBC about availability and participation.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 21, 2026, to July 21, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/PI3KAKTmTORMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Basho is on advisory committees with AstraZeneca Pharmaceuticals LP, Celcuity, Novartis, and Pfizer Inc; has consulting agreements with AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, and Pfizer Inc; has contracted research with AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, and Scorpion Therapeutics; is on data and safety monitoring boards/committees for Pfizer Inc; and is on speakers bureaus with DAVA Oncology and MDOutlook; and has nonrelevant financial relationships with Community Health Media, OncLive, and Targeted Oncology. Ms Rikal is on advisory committees with Stemline Therapeutics Inc; and has consulting agreements with and is on speakers bureaus for AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

MODERATOR
Dr Wander has consulting agreements with Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, and Veracyte Inc; and has contracted research with Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, and Stemline Therapeutics Inc.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, and Genentech, a member of the Roche Group.

Release date: July 21, 2026
Expiration date: July 21, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Faculty

Nurse

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Nurse

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with breast cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel CDK4/6 inhibitors for HR-positive breast cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of HR-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 21, 2026, to July 21, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith has consulting agreements with Amplity; is on speakers bureaus with AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, and Stemline Therapeutics Inc; and has nonrelevant financial relationships with ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, and Oncology Nursing News. Dr O’Regan is on advisory committees with Biotheranostics Inc, A Hologic Company; has consulting agreements with Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, and Regor Pharmaceuticals; has contracted research with Novartis and Puma Biotechnology Inc; and is on data and safety monitoring boards/committees for Gilead Sciences Inc.

MODERATOR
Dr Nanda is on advisory committees with AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, and Summit Therapeutics; and has contracted research with Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, and Relay Therapeutics.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Lilly and Novartis.

Release date: July 21, 2026
Expiration date: July 21, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Alexiou S et al. CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials. Cancers (Basel) 2025;17(21):3538. Abstract

Barrios CH et al. NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Breast 2024;Abstract 113MO.

Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med 2020;383(26):2557-70. Abstract

Crown J et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open 2025;10(11):105858. Abstract

de la Haba-Rodriquez J et al. ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria. ESMO 2024;Abstract LBA23.

Fasching PA et al. Ribociclib plus endocrine therapy in hormone receptor-positive/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol 2025;11(11):1364-72. Abstract

Goetz MP et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: Analyses from the monarchE study. NPJ Breast Cancer 2024;10(1):34. Abstract

Hamilton E et al. Impact of ribociclib dose reduction on efficacy in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in NATALEE. San Antonio Breast Cancer Symposium 2024;Abstract P1-11-16.

Hurvitz SA et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor-positive/HER2-/PIK3CA wild-type advanced breast cancer. J Clin Oncol 2026;44(12):1108-19. Abstract

Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract

Jhaveri KL et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med 2025;393(2):151-61. Abstract

Johnston S et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol 2026;37(2):155-65. Abstract

Johnston SRD et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(1):77-90. Abstract

Johnston SRD et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38(34):3987-98. Abstract

Kalinsky K et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4/6 inhibition: Results from the phase III postMONARCH trial. J Clin Oncol 2025;43(9):1101-12. Abstract

Kubeczko M et al. Efficacy of CDK 4/6 inhibitors and radiotherapy in breast cancer patients with brain metastases. J Clin Med 2023;12(5):2044. Abstract

Loibl S et al. Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy – PADMA study. San Antonio Breast Cancer Symposium 2024;Abstract LB1-03.

Lu Y-S et al. Final results of RIGHT Choice: Ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. J Clin Oncol 2024;42(23):2812-21. Abstract

Mayer EL et al. The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. ASCO 2025;Abstract 517.

Merz LE. A paradigm shift in neutrophil adverse event grading: Why now? Hemasphere 2025;9(10):e70242. Abstract

Metzger O et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 2026;394(5):451-62. Abstract

Metzger O et al. Central nervous system outcomes from the phase III PATINA trial (AFT-38). San Antonio Breast Cancer Symposium 2025;Abstract RF4-01.

Orlandi A. Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2- metastatic breast cancer with visceral crisis? Evaluating the emerging evidence. Discov Oncol 2025;16(1):982. Abstract

Slamon DJ et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 2024;42(9):994-1000. Abstract

Tolaney SM et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 2020;26(20):5310-9. Abstract

Turner NC et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med 2024;391(17):1584-96. Abstract

Faculty

Faculty

Beth Faiman

PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Adult Nurse Practitioner, Department of Hematology and Medical Oncology

Case Comprehensive Cancer Center, Cleveland, Ohio

Member, Population and Cancer Prevention Program

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Nurse

Mary Steinbach

PhD-c, DNP, FNP-C, APRN

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Lead Ambulatory Advanced Practice Clinician, Division of Hematology

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma (MM).

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for relapsed/refractory (R/R) MM in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with R/R MM.
• Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
• Educate patients with R/R MM about the mechanism of action of, available and emerging data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
• Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for R/R MM, and recognize the current clinical role of this form of treatment.
• Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 17, 2026, to July 17, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman is on advisory committees and has consulting agreements with Janssen Biotech Inc and Sanofi. 

Dr Lee has consulting agreements (paid to institution) with AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has consulting agreements (paid to self) with Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, and Takeda Pharmaceuticals USA Inc; has contracted research with AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc; and is on data and safety monitoring boards/committees for Allogene Therapeutics and Takeda Pharmaceuticals USA Inc. 

Ms Steinbach is on advisory committees with Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc; has contracted research with and is on speakers bureaus for Johnson & Johnson, Pfizer Inc, and Regeneron Pharmaceuticals Inc.

All of the relevant financial relationships above have been mitigated.

MODERATOR
Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Release date: July 17, 2026
Expiration date: July 17, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Faculty

Faculty

Bradley J Monk

MD

Florida Cancer Specialists & Research Institute, West Palm Beach, Florida

Medical Director, Late-Phase Research Program

University of Central Florida College of Medicine, Orlando, Florida

Professor

GOG Foundation, West Palm Beach, Florida

Vice President and Member, Board of Directors

GOG Partners, West Palm Beach, Florida

Co-Director

Nurse

Kathryn M Schlenker

MSN, WHNP-BC, AGNP-C

The University of Alabama at Birmingham, Birmingham, Alabama

Nurse Practitioner, Division of Gynecologic Oncology

Nurse

Jaclyn Shaver

MS, APRN, CNP, WHNP

Stephenson Cancer Center, OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology

Moderator

David M O'Malley

MD

The Ohio State University and The James Comprehensive Cancer Center, Columbus, Ohio

Director and Professor, Division of Gynecologic Oncology in Obstetrics and Gynecology, John G Boutselis Chair in Gynecologic Oncology

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with OC.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for OC in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Understand available clinical research findings with PARP inhibitors alone or in combination with bevacizumab as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC, and counsel appropriate individuals regarding personalized treatment recommendations.
• Appraise relevant biological, patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for this newly relevant biomarker.
• Understand the structural components and mechanism of action of antibody-drug conjugates (ADCs) directed at folate receptor alpha, and discuss current research findings with these agents.
• Assess available clinical research findings with immunotherapy in combination with chemotherapy for patients with platinum-resistant OC, and consider the integration of this therapeutic strategy into care for individuals with advanced disease.
• Review Phase III findings with selective glucocorticoid receptor modulators with chemotherapy for patients with platinum-resistant OC, and consider the current role of this combination in this treatment setting.
• Appreciate the side effects associated with various systemic therapies commonly employed for OC, and use this information to develop supportive management plans for patients.
• Recall the biological rationale for the evaluation of other ADCs with alternative targets (eg, HER2, CDH6, TROP2) for OC, and consider the current and future role of these agents.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 17, 2026, to July 17, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/OvarianCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Schlenker and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Monk has consulting agreements with AbbVie Inc, Alkermes, AstraZeneca Pharmaceuticals LP, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Mersana Therapeutics Inc, Mural Oncology Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, OncoC4, Panavance Therapeutics, Pfizer Inc, pharmaand GmbH, ProfoundBio, Regeneron Pharmaceuticals Inc, Seagen Inc, Sutro Biopharma, Takeda Pharmaceuticals USA Inc, Tubulis, Verastem Inc, Zai Lab, Zentalis Pharmaceuticals, Zymeworks Inc; and is on speakers bureaus with AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, ImmunoGen Inc, Merck, Takeda Pharmaceuticals USA Inc, Zai Lab.

MODERATOR
Dr O’Malley has consulting agreements — personal fees (consult and/or advisory boards) with AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Duality Biologics, Genmab US Inc, GSK, Lilly, Merck, MSD, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Verastem Inc, Zentalis Pharmaceuticals; has contracted research (institution received funds for research) with AbbVie Inc, Advaxis Inc, Agenus Inc, Alkermes, Aravive Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Deciphera Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Incyte Corporation, Iovance Biotherapeutics, Karyopharm Therapeutics, Leap Therapeutics Inc, Merck, Mersana Therapeutics Inc, MSD, Novartis, Novocure Inc, OncoC4, OncoQuest Inc, Pfizer Inc, pharmaand GmbH, Predictive Oncology Inc, Prelude Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc, Sumitomo Pharma America, Sutro Biopharma, Tesaro, A GSK Company, Verastem Inc; and is on data and safety monitoring boards/committees for Frantz Viral Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Release date: July 17, 2026
Expiration date: July 17, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.